What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk (research code NNC 26-0161). Its amino acid sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — was specifically engineered to activate the growth hormone secretagogue receptor type 1a (GHS-R1a) with high selectivity. First characterized in a landmark 1998 study by Raun et al., ipamorelin was identified as the first GHRP-receptor agonist with a selectivity for growth hormone (GH) release comparable to that of endogenous growth hormone-releasing hormone (GHRH).

What distinguishes ipamorelin from earlier growth hormone-releasing peptides like GHRP-6 and GHRP-2 is its remarkably clean hormonal profile. Even at doses more than 200 times the effective dose for GH release (ED50), ipamorelin does not significantly elevate ACTH, cortisol, or prolactin levels. This selectivity makes it one of the most targeted GH secretagogues available for research and clinical investigation.

Mechanism of Action: GHS-R1a Signaling Cascade

Ipamorelin exerts its effects through a well-characterized intracellular signaling pathway in anterior pituitary somatotrophs:

1. Receptor binding: Ipamorelin binds to GHS-R1a, a G protein-coupled receptor (GPCR) on the surface of pituitary somatotroph cells. GHS-R1a is the same receptor that responds to endogenous ghrelin, but ipamorelin activates it without the broad metabolic effects of native ghrelin.

2. G protein activation: Receptor engagement activates the Gq/11 heterotrimeric G protein, initiating the phosphoinositide signaling cascade.

3. PLC activation and second messenger generation: Activated Gq/11 stimulates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers — inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).

4. Calcium mobilization: IP3 binds to IP3 receptors on the endoplasmic reticulum, triggering the release of stored Ca2+ into the cytoplasm. DAG simultaneously activates protein kinase C (PKC), which modulates voltage-gated calcium channels to allow extracellular Ca2+ influx.

5. GH vesicle exocytosis: The resulting surge in intracellular Ca2+ concentration drives the fusion of GH-containing secretory vesicles with the plasma membrane, releasing GH into the pituitary venous circulation.

Why Ipamorelin Does Not Spike Cortisol or Prolactin

The selectivity of ipamorelin is its defining pharmacological feature. GHRP-6 and GHRP-2 activate not only GHS-R1a but also off-target pathways — GHRP-6 significantly stimulates ACTH release from corticotrophs (leading to cortisol elevation) and prolactin release from lactotrophs. GHRP-2, while more GH-potent, still produces measurable ACTH and prolactin responses.

Ipamorelin’s pentapeptide structure (incorporating the non-natural amino acid aminoisobutyric acid and D-amino acids) confers receptor selectivity that confines its action to the GH axis. The Raun et al. (1998) study demonstrated that ipamorelin’s ACTH and cortisol levels remained indistinguishable from GHRH-stimulated controls across the entire dose range tested. This means ipamorelin stimulates GH without disrupting the hypothalamic-pituitary-adrenal (HPA) axis or the prolactin axis — a critical advantage for research applications and clinical safety.

The CJC-1295 + Ipamorelin Stack: GHRH Push + Ghrelin Pull

One of the most widely discussed peptide combinations in regenerative medicine research is CJC-1295 (a GHRH analog) paired with ipamorelin. The rationale is rooted in GH physiology:

• CJC-1295 (the “push”): As a GHRH analog, CJC-1295 binds to GHRH receptors on somatotrophs and directly stimulates GH gene transcription and GH synthesis. It amplifies the baseline capacity for GH production.

• Ipamorelin (the “pull”): As a ghrelin mimetic, ipamorelin triggers the acute release of pre-formed GH vesicles by activating the GHS-R1a pathway. It also suppresses somatostatin tone, removing the brake on GH secretion.

Together, the GHRH push (increased GH production) combined with the ghrelin pull (increased GH release) produces a physiologically amplified GH pulse that exceeds what either peptide achieves alone. This synergistic mechanism mimics the natural interplay between hypothalamic GHRH and ghrelin in regulating pulsatile GH secretion.

Clinical Evidence

Phase II Trials for Post-Operative Ileus

Helsinn Therapeutics (which licensed ipamorelin from Novo Nordisk) conducted two Phase II randomized, placebo-controlled trials evaluating ipamorelin for post-operative ileus in bowel resection patients:

• NCT00672074 (2008-2009): 117 patients, Phase II proof-of-concept. Evaluated safety and efficacy of ipamorelin for managing post-operative ileus following bowel resection.

• NCT01280344 (2011-2014): 320 patients, Phase II confirmatory. Assessed whether ipamorelin could reduce time to recovery of gastrointestinal function after partial bowel resection with primary anastomosis.

While primary efficacy endpoints for accelerating GI recovery were not met, the safety data was informative: the overall incidence of treatment-emergent adverse events was 87.5% in the ipamorelin group versus 94.8% in the placebo group, confirming that ipamorelin was well tolerated over 7 days of dosing with an adverse event profile comparable to placebo.

GH Dose-Response and Selectivity Data

The foundational Raun et al. (1998) study established key pharmacological parameters:

• Ipamorelin produces dose-dependent GH release in rats and swine comparable in magnitude to GHRP-6
• No significant change in ACTH or cortisol at any dose tested, including doses 200-fold above the GH ED50
• No significant prolactin release
• GH response is blocked by a GHRH antagonist, confirming a GHRH-dependent mechanism
• Linear dose-response in healthy human volunteers from 0.01 to 0.1 mg/kg IV

Molecular Properties

Property	Value
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Formula	C38H49N9O5
Molecular Weight	711.85 Da
Exact Mass	711.3857 Da
XLogP	1.8
Topological Polar Surface Area	240.21 A2
Hydrogen Bond Donors	8
Hydrogen Bond Acceptors	8
Rotatable Bonds	19
Chiral Centers	4
PubChem CID	9831659
ChEMBL ID	CHEMBL58547
DrugBank ID	DB12370
CAS Number	170851-70-4
UNII	Y9M3S784Z6
Research Code	NNC 26-0161

Comparison: Ipamorelin vs GHRP-6 vs GHRP-2

Parameter	Ipamorelin	GHRP-6	GHRP-2
GH Release Potency	Moderate-high	Moderate	High (most potent GHRP)
GH Selectivity	Highest — GH only	Low — broad hormonal effects	Moderate — some off-target activity
Cortisol Elevation	None (even at 200x ED50)	Significant	Mild-moderate
ACTH Elevation	None	Significant	Mild-moderate
Prolactin Elevation	None	Moderate	Mild
Appetite Stimulation	Minimal	Strong (potent ghrelin activation)	Moderate
Hunger/Ghrelin Effect	Mild	Intense hunger spike	Moderate hunger
Water Retention	Mild	Moderate-significant	Moderate
Clinical Development	Phase II (post-operative ileus)	Research only	Approved in Japan (pralmorelin) for GH testing
Best Use Case	Clean GH pulse without side effects	Maximum GH + appetite stimulation	High-potency GH with acceptable side effects

Blood Markers Affected

Ipamorelin’s effects on measurable blood markers are well characterized:

• Growth Hormone (GH): Directly increased via pulsatile release from somatotrophs. Peak GH levels occur 30-45 minutes post-injection and return to baseline within 2-3 hours.
• IGF-1 (Insulin-like Growth Factor 1): Indirectly elevated as hepatic IGF-1 production increases in response to sustained GH signaling. Measurable increases develop over days to weeks of consistent dosing.
• Ghrelin: Ipamorelin mimics ghrelin at GHS-R1a but does not directly increase circulating ghrelin levels. Endogenous ghrelin regulation remains intact.
• Cortisol: No significant change — this is the defining clinical advantage over GHRP-6 and GHRP-2.
• Prolactin: No significant change at any tested dose.
• ACTH: No significant change, confirming no HPA axis disruption.
• Glucose/Insulin: GH has anti-insulin effects; repeated dosing may transiently increase fasting glucose and reduce insulin sensitivity. Monitoring recommended in insulin-resistant individuals.

Safety and Side Effects

Ipamorelin has demonstrated a favorable safety profile in the clinical data available. In Phase II trials involving over 400 patients, adverse event rates were comparable to placebo. The most common reported effects include transient headache, mild injection site reactions, and temporary water retention.

The absence of cortisol and prolactin stimulation eliminates several side effect categories seen with other GHRPs — notably the adrenal stress response, appetite surge, and reproductive hormone interference associated with GHRP-6. However, long-term human safety data beyond 7 days of dosing remains limited. Individuals considering ipamorelin should work with a qualified healthcare provider and monitor GH, IGF-1, fasting glucose, and insulin levels periodically.

Ipamorelin is not FDA-approved for any indication. All clinical use is off-label, and pharmaceutical-grade sourcing is critical to avoid contamination risks inherent in unregulated peptide markets.